{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:52:40Z","timestamp":1787003560082,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017964","name":"Tianjin Municipal Health Commission","doi-asserted-by":"publisher","award":["TJSJMYXYC-D2-026"],"award-info":[{"award-number":["TJSJMYXYC-D2-026"]}],"id":[{"id":"10.13039\/100017964","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-77889-3","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:20:06Z","timestamp":1730092806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617"],"prefix":"10.1038","volume":"14","author":[{"given":"Shangrong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranlu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"77889_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024 [J]. CA: a cancer journal for clinicians, 74(1): 12\u201349 (2024). https:\/\/doi.org\/10.3322\/caac.21820","DOI":"10.3322\/caac.21820"},{"issue":"3","key":"77889_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai, K., Mcmanus, J. M. & Sharifi, N. Hormonal therapy for prostate Cancer [J]. Endocr. Rev. 42 (3), 354\u2013373. https:\/\/doi.org\/10.1210\/endrev\/bnab002 (2021).","journal-title":"Endocr. Rev."},{"issue":"4","key":"77889_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","volume":"31","author":"R Ge","year":"2020","unstructured":"Ge, R. et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer [J]. Annals oncology: official J. Eur. Soc. Med. Oncol. 31 (4), 470\u2013479. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.002 (2020).","journal-title":"Annals oncology: official J. Eur. Soc. Med. Oncol."},{"issue":"8","key":"77889_CR4","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1021\/cr500171e","volume":"115","author":"S Banerjee","year":"2015","unstructured":"Banerjee, S., Pillai, M. R. & Knapp, F. F. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications [J]. Chem. Rev. 115 (8), 2934\u20132974. https:\/\/doi.org\/10.1021\/cr500171e (2015).","journal-title":"Chem. Rev."},{"issue":"4","key":"77889_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet, J. et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes [J. J. Nucl. Med. Off. Publ. Soc. Nuclear Med. 60 (4), 517\u2013523. https:\/\/doi.org\/10.2967\/jnumed.118.219352 (2019).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nuclear Med."},{"issue":"12","key":"77889_CR6","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1078-0432.Ccr-19-1485","volume":"26","author":"K Current","year":"2020","unstructured":"Current, K. et al. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity [J]. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 26 (12), 2946\u20132955. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1485 (2020).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"11","key":"77889_CR7","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh, A. et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET\/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J]. J. Nucl. Med. Off. Publ. Soc. Nuclear Med. 56 (11), 1697\u20131705. https:\/\/doi.org\/10.2967\/jnumed.115.161299 (2015).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nuclear Med."},{"issue":"7","key":"77889_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","volume":"23","author":"K Patell","year":"2023","unstructured":"Patell, K. et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review [J]. Expert Rev. Anticancer Ther. 23 (7), 731\u2013744. https:\/\/doi.org\/10.1080\/14737140.2023.2213892 (2023).","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"12","key":"77889_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer [J]. N. Engl. J. Med. 385 (12), 1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322 (2021).","journal-title":"N. Engl. J. Med."},{"key":"77889_CR10","doi-asserted-by":"publisher","unstructured":"Dhodapkar, M. M. et al. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study [J]. BMJ (Clinical Res. ed), 379, e071752. https:\/\/doi.org\/10.1136\/bmj-2022-071752 (2022).","DOI":"10.1136\/bmj-2022-071752"},{"issue":"5","key":"77889_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","volume":"37","author":"C Michel","year":"2017","unstructured":"Michel, C. et al. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles? [J]. Clin. Drug Investig. 37 (5), 415\u2013422. https:\/\/doi.org\/10.1007\/s40261-017-0503-6 (2017).","journal-title":"Clin. Drug Investig."},{"issue":"3","key":"77889_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1529-8019.2009.01233.x","volume":"22","author":"J Weaver","year":"2009","unstructured":"Weaver, J. et al. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA) [J]. Dermatol. Ther. 22 (3), 204\u2013215. https:\/\/doi.org\/10.1111\/j.1529-8019.2009.01233.x (2009).","journal-title":"Dermatol. Ther."},{"issue":"8","key":"77889_CR13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jama.2010.1205","volume":"304","author":"BM Psaty","year":"2010","unstructured":"Psaty, B. M. & Siscovick, D. S. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction [J]. Jama. 304 (8), 897\u2013898. https:\/\/doi.org\/10.1001\/jama.2010.1205 (2010).","journal-title":"Jama"},{"issue":"6","key":"77889_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate, A. & Evans, S. J. Quantitative signal detection using spontaneous ADR reporting [J]. Pharmacoepidemiol. Drug Saf. 18 (6), 427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742 (2009).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"77889_CR15","doi-asserted-by":"publisher","unstructured":"Elisabetta, P. et al. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) [M]\/\/ADEM K. Data Mining Applications in Engineering and Medicine. Rijeka; IntechOpen. : Ch. 12. (2012). https:\/\/doi.org\/10.5772\/50095","DOI":"10.5772\/50095"},{"key":"77889_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.11.017","author":"MP Huynh-Le","year":"2020","unstructured":"Huynh-Le, M. P. et al. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization [J]. Clin. Genitourin. Cancer, 18(3): 192\u2013200e192. https:\/\/doi.org\/10.1016\/j.clgc.2019.11.017 (2020)."},{"issue":"1","key":"77889_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions [J]. Pharmacoepidemiol. Drug Saf. 11 (1), 3\u201310. https:\/\/doi.org\/10.1002\/pds.668 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"77889_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports [J]. Pharmacoepidemiol. Drug Saf. 10 (6), 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"3","key":"77889_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W Dumouchel","year":"1999","unstructured":"Dumouchel, W. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System [J]. Am. Stat. 53 (3), 177\u2013190. https:\/\/doi.org\/10.1080\/00031305.1999.10474456 (1999).","journal-title":"Am. Stat."},{"issue":"4","key":"77889_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation [J]. Eur. J. Clin. Pharmacol. 54 (4), 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"77889_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer, E. M. et al. NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 3.2024 [J]. J. Natl. Compr. Cancer Network: JNCCN. 22 (3), 140\u2013150. https:\/\/doi.org\/10.6004\/jnccn.2024.0019 (2024).","journal-title":"J. Natl. Compr. Cancer Network: JNCCN"},{"issue":"2","key":"77889_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki, D. et al. Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer [J]. Eur. Urol. 86 (2), 164\u2013182. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010 (2024).","journal-title":"Eur. Urol."},{"issue":"4","key":"77889_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","volume":"85","author":"KN Chi","year":"2024","unstructured":"Chi, K. N. et al. Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer [J]. Eur. Urol. 85 (4), 382\u2013391. https:\/\/doi.org\/10.1016\/j.eururo.2023.12.004 (2024).","journal-title":"Eur. Urol."},{"issue":"4","key":"77889_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.34749","volume":"154","author":"E Almuradova","year":"2024","unstructured":"Almuradova, E. et al. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study [J]. Int. J. Cancer. 154 (4), 692\u2013700. https:\/\/doi.org\/10.1002\/ijc.34749 (2024).","journal-title":"Int. J. Cancer"},{"issue":"10276","key":"77889_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman, M. S. et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial [J]. Lancet (London England). 397 (10276), 797\u2013804. https:\/\/doi.org\/10.1016\/s0140-6736(21)00237-3 (2021).","journal-title":"Lancet (London England)"},{"issue":"1","key":"77889_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40880-019-0425-1","volume":"39","author":"X Zhang","year":"2019","unstructured":"Zhang, X. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer [J]. Cancer Commun. (London England). 39 (1), 76. https:\/\/doi.org\/10.1186\/s40880-019-0425-1 (2019).","journal-title":"Cancer Commun. (London England)"},{"issue":"13","key":"77889_CR27","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","volume":"42","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal, L. et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer [J]. Eur. J. Nucl. Med. Mol. Imaging. 42 (13), 1976\u20131983. https:\/\/doi.org\/10.1007\/s00259-015-3125-3 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"77889_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/cbr.2021.0318","volume":"37","author":"DR Fisher","year":"2022","unstructured":"Fisher, D. R. Perspectives on Internal Dosimetry for Optimized Radionuclide Therapy [J]. Cancer Biother. Radiopharm. 37 (3), 161\u2013163. https:\/\/doi.org\/10.1089\/cbr.2021.0318 (2022).","journal-title":"Cancer Biother. Radiopharm."},{"issue":"6","key":"77889_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/s1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi, K. et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial [J]. Lancet Oncol. 24 (6), 597\u2013610. https:\/\/doi.org\/10.1016\/s1470-2045(23)00158-4 (2023).","journal-title":"Lancet Oncol."},{"key":"77889_CR30","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T. et al. Data mining of the public version of the FDA Adverse Event Reporting System [J]. Int. J. Med. Sci., 10(7): 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013)."},{"key":"77889_CR31","doi-asserted-by":"publisher","unstructured":"Patnaik, S. et al. Metastatic spinal cord compression [J]. British journal of hospital medicine (London, England: 2020, 81(4): 1\u201310. DOI: (2005). https:\/\/doi.org\/10.12968\/hmed.2019.0399","DOI":"10.12968\/hmed.2019.0399"},{"key":"77889_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1749-6632.1998.tb09641.x","volume":"842","author":"PC Fox","year":"1998","unstructured":"Fox, P. C. Acquired salivary dysfunction. Drugs and radiation [J]. Ann. N. Y. Acad. Sci. 842, 132\u2013137. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb09641.x (1998).","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77889-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77889-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77889-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T05:07:40Z","timestamp":1730351260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77889-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77889"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77889-3","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"},{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The FAERS database is a public repository where reports of adverse events are voluntarily submitted by medical and non-medical professionals. The data used in our study are derived from this database, hence ethical approval and patient informed consent are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study does not require informed consent forms.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"25712"}}